Health Care and Environmental Contamination 2018
DOI: 10.1016/b978-0-444-63857-1.00012-7
|View full text |Cite
|
Sign up to set email alerts
|

Management of Environmental Contaminants From Health Care: Sustainable Pharmacy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 22 publications
0
3
0
Order By: Relevance
“…The distribution of pharmaceuticals in pharmaceutical wastewater can be described to be rather stable as the manufacturers mostly focus on single/ several products at one time. One characteristic of pharmaceutical wastewater is actually the recommendation to use end-of-pipe technology-the stability of the matrix makes the treatment easy to optimize; the higher concentration of the pollutant makes the treatment more cost-effective (Mantovani et al 2017;Kümmerer 2018). Thereby, industrial wastewater rich in pharmaceuticals should undergo special treatment at the place of origin before discharge into the environment or municipal WWTPs.…”
Section: Industrial Wastewatermentioning
confidence: 99%
See 1 more Smart Citation
“…The distribution of pharmaceuticals in pharmaceutical wastewater can be described to be rather stable as the manufacturers mostly focus on single/ several products at one time. One characteristic of pharmaceutical wastewater is actually the recommendation to use end-of-pipe technology-the stability of the matrix makes the treatment easy to optimize; the higher concentration of the pollutant makes the treatment more cost-effective (Mantovani et al 2017;Kümmerer 2018). Thereby, industrial wastewater rich in pharmaceuticals should undergo special treatment at the place of origin before discharge into the environment or municipal WWTPs.…”
Section: Industrial Wastewatermentioning
confidence: 99%
“…End-of-pipe solutions (namely-the reduction in the concentration of contaminants in the place where they are produced) seem to be encouraged in the case of pharmaceuticals (Kümmerer 2018). Nevertheless, advanced treatment processes are not compatible with sustainable development because they focus on end-of-pipe solutions linked to the abovementioned problems of the presence of transformation products (Leder et al 2015).…”
Section: Concernmentioning
confidence: 99%
“…The whole life cycle of a compound or a health-care product must be considered when making risk management and risk reduction decisions (Boxall and Kookana, 2018). Such life-cycle assessment can be made by various stakeholders in the health-care chain, including manufacturers, doctors, pharmacists, and patients (Kümmerer, 2018). Fortunately, within the past decades several environmental policies have emphasized the need for greater environmental responsibility and the development of strategies that encourage more sustainable practices at the international level (Boxall and Kookana, 2018).…”
Section: Possible Solutionsmentioning
confidence: 99%